The FDA has accepted Bausch + Lomb and Nicox’s new drug application for Vesneo for review, according to a press release from Valeant Pharmaceuticals. “The acceptance for review of the Vesneo NDA by the FDA marks an important milestone in our effort to bring a new treatment to patients with open angle glaucoma and ocular hypertension,” J. Michael Pearson, CEO and chairman of Valeant, said in the release.
PHILADELPHIA — Alcon’s partnership with Google is making strides in contact lens technology, focusing on products for presbyopia correction and for health monitoring in patients with diabetes, according to a presentation at the Wills Vision Research Center at Jefferson annual symposium.Jeff George, president and global head of Alcon, discussed progress in the development of smart contact lenses since the Alcon-Google partnership was announced in July 2014.
A modest reduction in the use of low-value services was seen among health care practices that participated in Medicare’s Pioneer ACO program, according to recently published data in JAMA Internal Medicine. Aaron L. Schwartz, PhD, department of health care policy at Harvard Medical School, and colleagues, constructed 31 claims-based measures of low-value services and analyzed data from 2009 to 2012 Medicare fee-for-service claims to assess whether the Medicare Pioneer ACO program reduced the use of low-value services. Schwartz and colleagues conducted a difference-in-differences analysis between Medicare fee-for-service beneficiaries using providers enrolled in the Pioneer ACO program and those using non-ACO providers (control group), before (2009 to 2011) and after (2012) Pioneer ACO contracts began.
A U.S. district court in Delaware issued rulings on three pending summary judgment motions in Glaukos’ lawsuit against Transcend Medical concerning Transcend’s CyPass micro-stent.According to a press release from Glaukos, the court ruled that the CyPass does not infringe on the Glaukos patents named in the lawsuit. The court also partly granted Transcend’s summary judgment motion of invalidity, which affects a small subset of claims in each of the Glaukos patents but not the primary claims of the patents.
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff
NICE — At the Euretina meeting, Ingrid Kreissig, MD, talks about her course on “Minimal Surgery” for retinal detachment. Her personal extraocular technique with an elastic sponge segmental buckle aims at causing minimal trauma to the eye to have fewer complications and better long-term function.